We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock

41 hedge funds and large institutions have $4.77M invested in Yarrow Bioscience, Inc. Common Stock in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

258% more capital invested

Capital invested by funds: $1.33M → $4.77M (+$3.44M)

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

21% more funds holding

Funds holding: 3441 (+7)

0.18% more ownership

Funds ownership: 0.31%0.49% (+0.18%)

Holders
41
Holders Change
+7
Holders Change %
+20.59%
% of All Funds
0.5%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
10
Reduced
7
Closed
4
Calls
Puts
Net Calls
Net Calls Change

YARW Hedge Fund Activity: Q4 2025 in Review

41 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q4 2025, worth a combined $4.77M — up 258% from $1.33M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new YARW positions and 4 closed out — a net gain of 7 holders — while 10 added to existing stakes and 7 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $512K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $285K sold.

  • 41 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q4 2025, up from 34 in Q3 2025.
  • Funds reported $4.77M of Yarrow Bioscience, Inc. Common Stock stock for Q4 2025, up 258% quarter-over-quarter.
  • 11 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q4 2025 and 4 closed out, a net change of +7 holders.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q4 2025 was Anson Funds Management, an estimated $512K added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q4 2025 was Baker Bros. Advisors, an estimated $285K sold.

Based on aggregated 13F filings for Q4 2025.